Sanofi Delivers 2024/25 U.S. Flu Vaccines

Sanofi, a global leader in vaccine production, has initiated the distribution of its influenza vaccines in the United States, preparing for the 2024/25 flu season. The initial shipments commenced on July 10, 2024, with further distributions planned through October. These vaccines will be sent to healthcare provider offices, pharmacies, and other immunization sites to support the fall immunization campaigns.

Sanofi, with over 125 years of experience in public health, vaccinates more than 500 million people annually worldwide. The company's extensive experience and commitment to disease prevention are highlighted by Thomas Grenier, Head of Vaccines for North America at Sanofi. Grenier emphasizes the importance of flu vaccinations in reducing the risk of serious complications such as pneumonia and cardiac events, especially for the most vulnerable populations.

Sanofi's flu vaccines for the U.S. market are trivalent, providing protection against two influenza A strains and one influenza B strain. These strains are selected based on a comprehensive review by the U.S. Food and Drug Administration (FDA), World Health Organization (WHO), and Centers for Disease Control and Prevention (CDC), among other public health experts. The selection is aimed at addressing the strains most likely to cause illness in the upcoming season.

Health authorities globally stress the importance of annual flu vaccination as one of the best measures for flu prevention and its complications. Sanofi's flu vaccine portfolio caters to a wide age range, from children as young as six months to adults aged 65 and older. For the 2024/25 season, the portfolio includes Fluzone High-Dose, Flublok, and Fluzone vaccines.

Fluzone, Flublok, and Fluzone High-Dose are designed to prevent influenza A and B strains contained in the vaccines. Fluzone is suitable for individuals from six months of age, Flublok for those 18 years and older, and Fluzone High-Dose for adults 65 years and older.

Safety is a critical consideration in vaccine administration. The primary side effects of Fluzone in children include pain or tenderness at the injection site, irritability, drowsiness, and muscle pain. In adults up to 64 years, common side effects are pain at the injection site, headache, and muscle pain, while those over 65 may experience pain at the injection site, headache, muscle pain, and general discomfort. For Flublok, typical side effects in adults 18 to 64 include pain at the injection site, headache, tiredness, and muscle pain, and in adults 65 and older, pain at the injection site, tiredness, and headache. Fluzone High-Dose in adults 65 and older commonly results in pain at the injection site, muscle pain, tiredness, and headache.

Sanofi, an innovative healthcare company, aims to transform medical practice by providing life-changing treatments and life-saving vaccines to millions globally. The company places sustainability and social responsibility at the core of its operations, striving to turn scientific breakthroughs into possible solutions for better health outcomes.